RBC Capital analyst Kennen MacKay said DBVT's withdrawal of Viaskin Peanut's FDA regulatory submission removes a major competitive commercial risk ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE